Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Vomiting 12Nausea 12Neoplasms 8Hematologic Neoplasms 5Anorexia 4Cachexia 3Breast Neoplasms 3Weight Loss 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Multiple Myeloma 2Lung Neoplasms 2Advanced Cancer 2Testicular Neoplasms 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Sedentary Behavior 1Radiation Injuries 1Prosthesis Failure 1Postoperative Nausea and Vomiting 1Pain 1Opioid-Related Disorders 1Nutrition Disorders 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Muscular Atrophy 1Multiple Endocrine Neoplasia Type 1 1Lymphoma 1Insulin Resistance 1Hyperlipidemias 1Hyperglycemia 1

Interventions

Insulin Glargine 4Insulin 3volagidemab 2Metformin 2Fulvestrant 2Alpelisib 2ziprasidone 1relacorilant 1pembrolizumab 1exemestane 1dapagliflozin 1Vildagliptin 1Tamoxifen 1Standard of Care 1Olanzapine 1Letrozole 1Insulin Lispro 1Insulin Aspart 1Injections 1DNA, Ribosomal 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hyperglycemia × Olanzapine × Clear all
NCT00910988 2018-07-18

Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

Washington University School of Medicine

Phase NA Completed
46 enrolled 38 charts
Endocrine

Hyperglycemia, Hyperlipidemias, Insulin Resistance, Multiple Endocrine Neoplasia Type 1, Sedentary Behavior

Data powered by HemOnc (CC BY 4.0) Colophon âš¡